BRISBANE, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the third quarter 2016 after the market closes on Wednesday, November 9, 2016.  Dr. Peter Maag, Chief Executive Officer, and Charles Constanti, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.

Individuals interested in listening to the conference call may do so by dialing (855) 420-0616 for domestic callers or (678) 304-6848 for international callers. Please reference Conference ID: 7448753. To listen to a live webcast, please visit the investor relations section of CareDx's website at: www.CareDx.com.

A replay of the call will be available beginning November 9, 2016 at 4:30 pm PT/7:30 pm ET through 4:30 pm PT/7:30 pm ET on November 10, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 7448753. The webcast will also be available on CareDx's website for one year following the completion of the call.

About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying risk of rejection in heart transplant recipients.

CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.

CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. For more information, please visit: www.CareDx.com.

Investor Relations Contact
Jamar Ismail, Vice President
Westwicke Partners, LLC Investor Contact
T: +1 415-513-1282
E: jamar.ismail@westwicke.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.